Poland· PL-100534148
Anktiva
A nogapendekin alfa and inbakicept product containing nogapendekin alfa inbakicept, registered in Poland by ImmunityBio Ireland Limited. The same ATC class is registered in 7 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nogapendekin alfa and inbakicept is registered in 7 of 19 countries.
Countries holding a registration under ATC L03AC03 (nogapendekin alfa and inbakicept), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Nogapendekin alfa and inbakicept · ATC L03AC03
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Nogapendekin alfa inbakicept
- Manufacturer
- ImmunityBio Ireland Limited
- Country
- Poland (PL)
- ATC code
- L03AC03
- ATC class
- Nogapendekin alfa and inbakicept
- Defined daily dose
- 12.5 mcg, intravesikal
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nogapendekin alfa and inbakicept in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAnktiva 400 µgImmunityBio Ireland
- CzechiaANKTIVAImmunityBio Ireland Limited, Dublin
- FinlandANKTIVAImmunitybio Ireland Limited
- IcelandANKTIVAImmunityBio Ireland Limited
- NetherlandsANKTIVA 400 microgram concentraat voor intravesicale suspensieImmunityBio Ireland Limited
- SwedenANKTIVA 400 mikrogram/0,4 mg Koncentrat till intravesikal suspensionImmunityBio Ireland Limited
- United StatesANKTIVAAltor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Anktiva
- Liechtenstein · Anktiva
- Norway · Anktiva
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a97d0b08-e722-4503-a0be-1b1227f8fb25 GET /v1/drugs/a97d0b08-e722-4503-a0be-1b1227f8fb25?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania zawiesiny do wstrzykiwań",
"source": "urpl",
"strength": "400 mcg",
"packaging": "Rp ¦ EU/1/25/2002/001 ¦ 166077\n1 fiol. 0,4 ml",
"substance": "Nogapendekin alfa inbakicept 400 mcg",
"common_name": "Nogapendekin alfa inbakicept",
"pl_product_id": "100534148",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about nogapendekin alfa and inbakicept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.